China New Holdings (08125): Li Yixuan resigns as an independent non-executive director.
Zhongxin Holdings (08125) announced that Ms. Li Yixuan has resigned as an independent non-executive director, member of the company audit committee, company nomination committee, company remuneration committee, and compliance committee due to her other business commitments, with effect from June 15, 2026.
CHINA NEW HLDGS (08125) announced that as of June 15, 2026, Ms. Li Yixuan has resigned as an independent non-executive director, a member of the company's audit committee, nomination committee, remuneration committee, and compliance committee due to her other business commitments.
Related Articles
New stock news | Din Tai Pharmaceuticals once again submits an application to the Hong Kong Stock Exchange, becoming the largest CRO in the field of non-clinical research for Chinese cardiovascular and metabolic diseases.
EVEREST MED (01952) has been granted exclusive rights by Dimerix to develop and commercialize DMX-200 in Greater China, South Korea, and several Southeast Asian countries.
New Stock News | Lico Pharmaceuticals files second application to Hong Kong Stock Exchange for the development of small molecule inhibitors for the treatment of autoimmune and inflammatory diseases.
New stock news | Din Tai Pharmaceuticals once again submits an application to the Hong Kong Stock Exchange, becoming the largest CRO in the field of non-clinical research for Chinese cardiovascular and metabolic diseases.
EVEREST MED (01952) has been granted exclusive rights by Dimerix to develop and commercialize DMX-200 in Greater China, South Korea, and several Southeast Asian countries.
New Stock News | Lico Pharmaceuticals files second application to Hong Kong Stock Exchange for the development of small molecule inhibitors for the treatment of autoimmune and inflammatory diseases.
RECOMMEND
